Malaria Clinical Trial
Official title:
Randomized, Double-Blind, Placebo-Controlled, Regimen Optimization Study of a Radiation-Attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults
Verified date | January 2020 |
Source | Sanaria Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a phase 1, randomized regimen optimization study of PfSPZ Vaccine in healthy Equatoguinean volunteers to determine if a condensed, rapid immunization regimen is safe and efficacious. Four different regimens 4 weeks or less in duration will be evaluated for safety, tolerability, immunogenicity, and protective efficacy in comparison to a gold standard 16-week regimen.
Status | Completed |
Enrollment | 104 |
Est. completion date | March 12, 2019 |
Est. primary completion date | March 12, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Healthy males and non-pregnant/non-lactating females, age 18 to 45 years at time of enrollment. 2. Provision of signed and dated informed consent form. 3. Demonstrate understanding of the study by responding correctly to 10 out of 10 true/false statements about the trial (a maximum of two additional attempts will be granted for those who fail to respond correctly to all true/false statements in their first attempt). 4. Stated availability and willingness to comply with all study procedures and visits for the duration of the trial, including the required vaccination and post-CHMI ward observation period. 5. Able to understand and communicate in Spanish, the national language of Equatorial Guinea 6. Be in good general health as evidenced by medical history, screening physical examination and laboratory findings. 7. Females of child bearing potential must agree to use injectable medroxyprogesterone for at least 4 weeks prior to enrollment and agree to continue to use medroxyprogesterone during the entire study period. 8. Female subjects must not be pregnant (as demonstrated by a negative urine pregnancy test) at enrollment and prior to each immunization. 9. Body Mass Index (BMI) of 18 to 30 kg/m2. 10. At least one year of residence on Bioko Island, Equatorial Guinea, and living close enough to Baney Clinical Research Center and Sampaka Hospital to be able to attend the required appointments at the study center. 11. Agree to release medical information and inform a study doctor about contraindications for participation in the study. 12. Willingness to be attended to by a study doctor and take all medications prescribed during the study period. 13. Agree to provide contact information of a third-party household member or close friend to the study team. 14. Agree not to participate in another clinical trial during the study period. 15. Agree not to donate blood during the study period. 16. Willing to undergo HIV, hepatitis B (HBV) and hepatitis C (HCV) tests. 17. Reachable by telephone for adverse event review. Exclusion Criteria: 1. Known allergic reactions to components of PfSPZ Vaccine, PfSPZ Challenge, or artemether-lumefantrine (AL). 2. Having received an investigational malaria vaccine in the last 5 years. 3. Having received any non-live vaccine in the 14 days prior to enrollment, any live vaccine in the 28 days prior to enrollment or three or more of any type of vaccine in the four months prior to enrollment. 4. Participation in any other clinical study involving investigational medicinal products including malaria drugs within 30 days prior to enrollment. 5. History of arrhythmias, prolonged QT-interval or other cardiac disease, or clinically significant abnormalities on electrocardiogram (ECG) at screening. 6. History of non-febrile seizures or complex febrile seizures. 7. History of cardiac disease in a 1st or 2nd degree relative when <50 years of age. 8. A chronic illness including diabetes mellitus, cancer, HIV/AIDS, tuberculosis. 9. History of illicit drug or alcohol use that interferes with normal social function. 10. The use of chronic immunosuppressive drugs or other immune modifying drugs within three months of study onset (inhaled and topical corticosteroids are allowed) and during the study period. 11. Any clinically significant deviation from the normal range in biochemistry, hematology or urinalysis tests. 12. Positive HIV, hepatitis B virus or hepatitis C virus serologic tests. 13. Signs and symptoms of tuberculosis (e.g., chronic cough, night sweats, chronic fever, enlarged lymph nodes, unintended weight loss), or risk factors in an otherwise healthy person in combination with a positive tuberculin skin test (TST). 14. Symptoms, physical signs and/or laboratory values suggestive of systemic disorders including renal, hepatic, blood, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric, and other conditions which could interfere with the interpretation of the study results or compromise the health of the volunteer. 15. Any medical, psychiatric, social or occupational condition or situation that, in the judgment of the PI, impairs the volunteer's ability to give informed consent, increases the risk to the volunteer of participation in the study, affects the ability of the volunteer to participate fully in the study, or might negatively impact the quality, consistency or interpretation of data derived from their participation in the study. |
Country | Name | City | State |
---|---|---|---|
Equatorial Guinea | Baney Clinical Research Center | Santiago De Baney | Bioko Island |
Lead Sponsor | Collaborator |
---|---|
Sanaria Inc. | Atlantic Methanol Production Company, Equatorial Guinea (EG) liquefied natural gas (LNG), Government of Equatorial Guinea, Ifakara Health Institute, Marathon Oil Corporation, Noble Oil Services, Swiss Tropical & Public Health Institute |
Equatorial Guinea,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence and type of Adverse Events (AEs) | Occurrence of solicited local AEs during priming vaccination and a 3-day surveillance period after priming and boost vaccinations. Occurrence of solicited systemic AEs during priming vaccination and a 7-day surveillance period after priming and boost vaccinations. Occurrence of unsolicited AEs during priming vaccination and a 14-day surveillance period after priming and boost vaccinations. Occurrence of serious adverse events (SAEs) during the study. |
Day of first immunization until 1 year | |
Secondary | Proportion of volunteers who become parasitemic will be recorded, detected by thick blood smear microscopy (TBS) and/ or quantitative real time polymerase chain reaction (qPCR) | Development of Pf parasitemia by TBS following CHMI Development of Pf parasitemia by qPCR following CHM |
Post first immunization uptil 56 days post-CHMI | |
Secondary | Level of Antibodies against Pf proteins in volunteer sera | Antibody titres to pre-erythrocytic stage and erythrocytic stage antigens[PfCSP, PfLSA-1, PfEBA-175 , PfMSP-1, PfMSP-5, EXP-1] by ELISA Antibody titres to Pf sporozoites, asexual and sexual erythrocytic stage parasites by IFA. Analysis of antibodies to proteins in the Pf proteome array chip. |
Post first immunization uptil 56 days post-CHMI | |
Secondary | Inhibitory Capacity of Volunteer Sera against in vitro Sporozoite Invasion of Hepatocytes | Capacity of sera from immunized volunteers to inhibit sporozoite invasion (ISI) of hepatocytes in vitro by ISI assay | Post first immunization uptil 56 days post-CHMI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04601714 -
Baseline Cohort Malaria Morbidity Study
|
||
Withdrawn |
NCT04020653 -
A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria
|
Phase 2 | |
Terminated |
NCT04368910 -
Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria
|
Phase 3 | |
Completed |
NCT03641339 -
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
|
N/A | |
Completed |
NCT02544048 -
Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
|
||
Completed |
NCT00527163 -
Role of Nitric Oxide in Malaria
|
||
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Active, not recruiting |
NCT04704674 -
Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
|
||
Completed |
NCT03276962 -
Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age
|
Phase 2 | |
Completed |
NCT04966871 -
Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults
|
Phase 1 | |
Completed |
NCT00289185 -
Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
|
Phase 2 | |
Recruiting |
NCT03937817 -
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
|
||
Active, not recruiting |
NCT06153862 -
Africa Ready Malaria Screening
|
N/A | |
Completed |
NCT04545905 -
Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
|
||
Recruiting |
NCT06278181 -
Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
|
||
Completed |
NCT02793622 -
Prevention of Malaria in HIV-uninfected Pregnant Women and Infants
|
Phase 3 | |
Withdrawn |
NCT02793414 -
Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
|
||
Completed |
NCT02909712 -
Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania
|
Phase 2 | |
Withdrawn |
NCT02793388 -
A Trial on Supervised Primaquine Use in Ethiopia
|
Phase 4 | |
Completed |
NCT02315690 -
Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland
|
Phase 3 |